Recent Updates — SUPN
Supernus Pharmaceuticals reported third-quarter total revenues of $226.8 million, an 18% increase from the prior year period, driven by strong growth in its four key products: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. Net product sales reached $178.6 million, while collaboration revenue from Biogen’s ZURZUVAE sales totaled $41.7 million. The company also raised its full-year 2026 total revenue guidance to a range of $875 million to $900 million and adjusted operating earnings guidance to $160 million–$180 million. Additionally, Supernus announced that its all-stock merger with Indivior Pharmaceuticals is expected to close on November 2, 2026, creating a diversified CNS biopharmaceutical leader. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases.
On October 20, 2026, Supernus Pharmaceuticals terminated its uncommitted demand revolving credit facility with UBS Bank USA. The termination was executed in anticipation of the company's previously announced business combination with Indivior Pharmaceuticals pursuant to an Agreement and Plan of Merger dated August 1, 2026. As of the termination date, no advances or obligations were outstanding under the facility, and no early termination penalties were incurred. The bank’s security interests in the collateral were released upon termination. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for neurological disorders.
The U.S. Food and Drug Administration has recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl), a treatment for motor fluctuations in adults with advanced Parkinson’s disease. This market exclusivity began on February 3, 2025, the date of initial FDA approval. Additionally, Supernus submitted a supplemental New Drug Application to the FDA for a second supplier for ONAPGO and expects potential approval by mid-year 2027. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases.
Supernus Pharmaceuticals, Inc. held a special meeting of its stockholders on October 15, 2026, to vote on the proposed Merger Agreement with Indivior Pharmaceuticals Inc. The proposal to adopt the Merger Agreement was approved by 48,249,532 votes in favor, compared to 235,601 against and 67,004 abstentions. A separate non-binding advisory vote on executive compensation related to the transaction received 32,688,410 votes for and 15,847,350 against. The merger involves Merger Sub merging with Supernus, which will continue as a wholly-owned subsidiary of Indivior. Supernus Pharmaceuticals operates in the pharmaceutical industry.
Supernus Pharmaceuticals, Inc. announced a proposed merger of equals with Indivior Pharmaceuticals Inc., creating a leading U.S. biopharmaceutical company focused on central nervous system diseases. The all-stock transaction is expected to close in the fourth quarter of 2026, subject to stockholder and regulatory approvals. Jack A. Khattar will serve as CEO of the combined entity. The merged company will combine Supernus's franchises (Qelbree, Zurzuvae, Onapgo, Gocovri) with Indivior's (Sublocade, Suboxone), generating approximately $2.16 billion in trailing twelve-month net revenue as of June 30, 2026. The filing references a Special Dividend funded by additional indebtedness to be incurred by the combined company. Supernus Pharmaceuticals operates in the biopharmaceutical industry, developing and commercializing treatments for central nervous system disorders.